298 patents
Page 7 of 15
Utility
Tricyclic Fused Thiophene Derivatives As Jak Inhibitors
16 Dec 21
The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
Yun-Long Li, Wenyu Zhu, Song Mei, Joseph Glenn
Filed: 12 Aug 21
Utility
Imidazopyridazine Compounds and Uses Thereof
16 Dec 21
Jun Pan, Yu Bai, Liangxing Wu, Wenqing Yao
Filed: 10 Jun 21
Utility
Combination Therapy for Treatment of Myeloproliferative Neoplasms
9 Dec 21
The present application relates to treatment of myeloproliferative neoplasms using the JAK1/JAK2 inhibitor, ruxolitinib, in combination with a BET protein inhibitor, 2,2,4-trimethyl-8-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-1,4-benzoxazin-3(4H)-one, wherein the combination is unexpectedly synergistic.
Matthew Stubbs, Phillip C. Liu
Filed: 2 Jun 21
Utility
Processes of Preparing a JAK1 Inhibitor
9 Dec 21
The present application provides processes for preparing 4-[3-(cyanomethyl)-3-(3′,5′-dimethyl-1H, 1′H-4,4′-bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide, and phosphoric acid salt thereof, which is useful as a selective (Janus kinase 1) JAK1 inhibitor, as well as salt forms and intermediates related thereto.
Jiacheng Zhou, Yingrui Dai, Zhongjiang Jia, Yongchun Pan, James M. Parks, Anthony J. Tomaine, Jianji Wang, Aibin Zhang
Filed: 2 Jun 21
Utility
Pyrazolopyridine Compounds and Uses Thereof
9 Dec 21
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds.
Oleg Vechorkin, Jun Pan, Kai Liu, Alexander Sokolsky, Anlai Wang, Hai Fen Ye, Qinda Ye, Wenqing Yao
Filed: 7 Jan 21
Utility
Heterocyclic Compounds As Immunomodulators
9 Dec 21
Liangxing Wu, Jingwei Li, Wenqing Yao
Filed: 18 Aug 21
Utility
Substituted Tricyclic Compounds As FGFR Inhibitors
9 Dec 21
The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
Liangxing Wu, Colin Zhang, Chunhong He, Liang Lu, Wenqing Yao
Filed: 2 Jun 21
Utility
Pyrazolopyrimidine Compounds and Uses Thereof
2 Dec 21
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds.
Oleg Vechorkin, Kai Liu, Jun Pan, Alexander Sokolsky, Hai Fen Ye, Qinda Ye, Wenqing Yao, Joshua Hummel
Filed: 23 Apr 21
Utility
Heterocyclic Compounds As Immunomodulators
25 Nov 21
Liangxing Wu, Zhiyong Yu, Fenglei Zhang, Wenqing Yao
Filed: 17 Dec 20
Utility
Fused Tricyclic Kras Inhibitors
18 Nov 21
Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds.
Wenyu ZHU, Xiaozhao WANG, Artem SHVARTSBART, Chao Qi, Rocco Policarpo, Wenqing Yao
Filed: 15 Apr 21
Utility
Fused Pyrimidine Compounds As Kras Inhibitors
18 Nov 21
Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds.
Gia Hoang, Xiaozhao Wang, Wenqing Yao
Filed: 12 May 21
Utility
Heterocyclic Compounds As Immunomodulators
11 Nov 21
Liangxing Wu, Bo Shen, Jingwei Li, Zhenwu Li, Kai Liu, Fenglei Zhang, Wenqing Yao
Filed: 11 Dec 20
Utility
Use of Pyrazolopyrimidine Derivatives for the Treatment of PI3K-DELTA Related Disorders
28 Oct 21
Yun-Long Li, Andrew P. Combs, Eddy W. Yue, Song Mei, Brent Douty
Filed: 30 Jun 21
Utility
Tricyclic Heteroaryl Compounds As Sting Activators
28 Oct 21
The present application provides tricyclic heteroaryl compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
Liangxing Wu, Yingda Ye, Wenqing Yao
Filed: 4 May 21
Utility
Heterocyclic Compounds As Immunomodulators
14 Oct 21
Kaijiong Xiao, Fenglei Zhang, Liangxing Wu, Wenqing Yao
Filed: 19 Nov 20
Utility
Salts of an LSD1 Inhibitor and Processes for Preparing the Same
30 Sep 21
The present invention relates to processes and intermediates for preparing 3-(cyanomethyl)-3-(4-{[(1R,2S)-2-phenylcyclopropyl]amino}piperidin-1-yl)azetidine-1-sulfonamide, and salts and solid forms thereof, which selectively modulate demethylase.
Zhongjiang Jia, Wayne Han, Yongchun Pan, Timothy Martin, Jiacheng Zhou, Qun Li
Filed: 12 Mar 21
Utility
1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
30 Sep 21
The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
Andrew P. Combs, Thomas P. Maduskuie, Jr., Nikoo Falahatpisheh
Filed: 4 Jun 21
Utility
Combination Therapy Comprising Axl/mer and PD-1/PD-L1 Inhibitors
9 Sep 21
The present disclosure relates to methods of treating cancer by administering a compound, which is an AXL/MER kinase inhibitor, in combination with an antibody, or an antibody fragment thereof, that binds to PD-1.
Jonathan Rios-Doria, Holly K. Koblish
Filed: 5 Mar 21
Utility
Tricyclic Compounds As Inhibitors of Kras
2 Sep 21
Xiaozhao Wang, Wenyu Zhu, Jeffrey Yang, Alexander Sokolsky, Chunhong He, Zhenwu Li, Chao Qi, Yong Li, Pei Gan, Peter Carlsen, Gia Hoang, Heeoon Han, Chenyin Marshall Law, Fenglei Zhang, Padmaja Polam, Le Zhao, Liangxing Wu, Wenqing Yao
Filed: 8 Jan 21
Utility
Fused Pyrimidine Derivatives As A2A / A2B Inhibitors
26 Aug 21
Xiaozhao Wang, Heeoon Han, Matthew S. McCammant, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Le Zhao
Filed: 27 Jan 21